This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020. Taking top-spot in the ranking, Exscientia has almost quadrupled its revenue in the last two years, a remarkable achievement and even more so considering the current climate. Turn to page 20 for an in-depth look at the other companies reaching new heights and what’s fuelling their success.
Elsewhere, on page 17, John Pinching and three pharma experts discuss the nature of the relationship between the pharma industry and the NHS and the catalysts for a new dynamic between these two giants of healthcare, while on page 28 the team at Veeva outline their expectations for the life sciences industry in 2021.
We also take another look at the microbiome and the growing realisation of its importance in several disease states and promise in the development of new targeted therapies. On page 38, Anthony Finbow describes how the science of microbiomes will increasingly contribute to research outcomes, while on page 40 Dr Tom Williams provides a close look at the relationship between the microbiome and melanoma.
The last decade has brought pharma and the NHS much closer, but while the union is often inspirational, it is also – like any long-term relationship – a bit complicated. Three experts discuss the future of the pharma-NHS dynamic.
Supplementing disease modelling with microbiome data is set to enable the life sciences industry to understand more about how drugs interact with different people, and devise more targeted treatments. Anthony Finbow explains how the science of microbiomes will increasingly contribute to pharma research outcomes